医薬品の開発に
「実りある」
患者・市民参画を育てる
Multi-stakeholder Co-creation
Social co-creation with patients and public
Inclusive and sustainable participation from diverse backgrounds
Equitable and reciprocal benefits
Ongoing opportunities for mutual learning – not just receiving support or making requests
Concrete actions
Robust planning to return value to society
Clinical Trial Ambassador Project
Empirical research 'Using PED as Evidence'
A pilot case study 'Building PED using metaverse'
Patient-focused clinical trial ecosystem
Supporting citizen science
Interdisciplinary Approach to Science
Empirical research activities that foster patient and public involvement (PPI)
A Focus on Societal Implementation
Consultation to implement PPI
We offer consultations on PPI
in medicines development and clinical research.
Our team—representing various professional backgrounds—works with
companies, researchers, healthcare providers, and patient groups
to help put PPI into practice.
Participation in PFMD's initiative
Patient engagement and patient experience data
Patient engagement in health technology assessment
Global clinical trials ecosystem
Co-hosted by 1st PEOF+ Asia Pacific in Manila in 2026.
A Global Perspective
Systematizing PPI through international collaboration
Events & Projects
Our Milestones
2020 In Austria, Boehringer Ingelheim and European Patients' Academy on Therapeutic Innovation (EUPATI) jointly launched the Clinical Trial Ambassador Project. The first training sessioin for patient organisations was delivered.
2021 Bringing Patient Education to Japan - Boehringer Ingelheim, patient organisations, and researchers comes together to design a Japanese version of the Clinical Trial Ambassador Project.
2022 Collaboration beyond Organizational Boundaries - Volunteers from pharmaceutical companies, patient organisations, and academia worked togather to deliver the first Clinical Trial Ambassador Training program in Japan. Six patient representatives completed the training and became Clinical Trial Ambassadors.
2024 Expanding Innovation for Society - To strengthen the public value, transparency, and credibility of the Project, its governing body was established as nonprofit. On April 25, YORIAILab was officially founded.
2025 Building a Co-creation Community - To further advance PPI in healthcare and medicines development, YORIAILab expanded its activities beyond the Clinical Trial Ambassador Project, strengthening education, partnerships, and research. By August 2026, more than 60 patients and members of the public had completed the training program and becoming contributors to a growing co-creation community.
Highlights
Latest information on events and resources ➡️
Clinical Trial Ecosystem
To advance a healthcare ecosystem shaped by patient perspectives, we contribute to discussions on the implementation of Decentralized Clinical Trials (DCTs). We organize standing workshops with Clinical Trial Ambassadors to explore the future of DCTs from the patient perspective. We also collaborate with medical institutions to support the implementation of PPI in clinical research.
News
Latest information on events and resources ➡️
2026.8.26 [Latest ]
We held orientation sessions for the 7th Clinical Trial Ambassador Training Program on the 24th and 26th. Twenty-two participants representing diverse backgrounds and perspectives will learn and grow together over the next six months.
2026.8.26 [Latest ]
We held orientation sessions for the 7th Clinical Trial Ambassador Training Program on the 24th and 26th. Twenty-two participants representing diverse backgrounds and perspectives will learn and grow together over the next six months.
2026.8.20 [Latest ]
Today, we officially launched the International Affairs Team, which was established at our Annual General Meeting in June. The team starts with six members. Building on our long-standing collaboration with PFMD, we will expand YORIAILab’s international activities by strengthening partnerships with patient organizations worldwide, participating in international projects, and sharing our knowledge and experiences with the global community.
2026.8.20 [Latest ]
Today, we officially launched the International Affairs Team, which was established at our Annual General Meeting in June. The team starts with six members. Building on our long-standing collaboration with PFMD, we will expand YORIAILab’s international activities by strengthening partnerships with patient organizations worldwide, participating in international projects, and sharing our knowledge and experiences with the global community.
2026.8.18 [Latest ]
We held our 23rd Lunchtime Short Seminar, featuring a presentation by Manami Fujii of Fukuyama University on the topic of “The Experience of Being a Sibling of a Person with Illness.” Ms. Fujii shared her personal experiences, thoughts, and challenges as a sibling, as well as her relationships with family members and those around her. Her talk provided valuable insights and an opportunity to reflect on how support for siblings can be improved and strengthened.
2026.8.9
At the Japan Cancer Forum, we exhibited an awareness booth on clinical trials and patient/citizen participation over two days, August 8th and 9th. More than 200 people visited our booth. On the first day at the event venue, we conducted a simulated experience of the recently popular Patient Preference Study, and more than 30 people participated in the live experience.
2026.8.8
We've created a flyer to help patients and the public learn more about Patient Experience Data (PED), which utilizes patients' experiences to improve healthcare. Please feel free to use it.
2026.7.29
All curriculum for the 6th Clinical Trial Ambassador Training Program has been completed. Those who have completed the training will now be active in various fields as Clinical Trial Ambassadors. We look forward to working with you.
2026.7.21
We held our 22nd Lunchtime Short Seminar. We explained the key points for interpreting the currently trending international regulatory guidelines on patient preference information, from the perspective of patient and public participation (PPI). This topic will also be covered at the DIA Bioethics Community Seminar (held online on August 25th, free of charge, co-sponsored by YORIAILab) ➡️ . If you would like to learn more in-depth, please join us there as well.
2026.7.15
At the 7th installment of "Make Hope, Create the Future" – Turning Patient Value into Data: PED, Patient Preferences, HTA, and the Ethics of its Use – (hosted by the NPO Lung Cancer Patients Association One Step, via YouTube Live) ➡️ , I spoke with Hayley Chapman of PFMD about our efforts to turn patient value into data (Patient Experience Data).
Public consultation
Public comment collection on new systems and guidelines regarding patient and public involvement
There are currently no open public consultations.
If you have any questions, please contact us here: ✉ nobutaka.yagi@yoriailab.com
